본문 바로가기
KERD
논문KCI 등재

코로나바이러스 감염증-19 백신 이상반응

Adverse Reactions of COVID-19 Vaccines

조은정
대한이비인후과학회 부산,울산,경남 지부회 (The Busan, Ulsan, Gyeoungnam Branch of The Korean Society of Otolaryngology)|2022.06|임상이비인후과 (Journal of Clinical Otolaryngology)|제33권 제2호|pp. 92-104|DOI 10.35420/jcohns.2022.33.2.92

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

COVID-19Drug-related side effects and adverse reactionsVaccines.
주제분류이비인후과학

초록

Various adverse events following immunization to coronavirus disease 2019 (COVID-19) vaccines have been reported as the administration of vaccines has been activated to end the COVID-19 pandemic. The most common symptoms are adverse reactions occurring in the immunogenicity process of reactogenicity. In addition, cutaneous adverse reactions, cardiovascular adverse reactions, neurological adverse reactions, and hematological adverse reactions have been reported. Thrombosis with thrombocytopenia syndrome, myocarditis, pericarditis, anaphylaxis, Guillain–Barré syndrome, and capillary leak syndrome have been severe adverse reactions. The COVID-19 vaccine dosing is a way to lower the fatality rate, not just the COVID-19 infection. Therefore, it is essential that we understand the reported adverse reactions to the COVID-19 vaccine for safe dosing and take appropriate action for adverse events.

Abstract

Various adverse events following immunization to coronavirus disease 2019 (COVID-19) vaccines have been reported as the administration of vaccines has been activated to end the COVID-19 pandemic. The most common symptoms are adverse reactions occurring in the immunogenicity process of reactogenicity. In addition, cutaneous adverse reactions, cardiovascular adverse reactions, neurological adverse reactions, and hematological adverse reactions have been reported. Thrombosis with thrombocytopenia syndrome, myocarditis, pericarditis, anaphylaxis, Guillain–Barré syndrome, and capillary leak syndrome have been severe adverse reactions. The COVID-19 vaccine dosing is a way to lower the fatality rate, not just the COVID-19 infection. Therefore, it is essential that we understand the reported adverse reactions to the COVID-19 vaccine for safe dosing and take appropriate action for adverse events.

참고문헌 (77)

  1. "Mortality analyses" (2022)[URL]
  2. Kang Hyun Mi, "코로나바이러스 감염증-19 백신에 대한 업데이트 및 소아청소년에서의 고려사항", Pediatric Infection and Vaccine, 28(1), pp.7~20 (2021), 대한소아감염학회[DOI]
  3. 정은희, "코로나바이러스감염증-19 (coronavirus disease 2019) 백신과 이상 반응", Allergy Asthma & Respiratory Diseases, 9(3), pp.124~135 (2021), 대한 소아알레르기 호흡기학회[DOI]
  4. Wise J, "COVID-19 : UK approves Novavax’s protein based vaccine", BMJ, 376, pp.o309~ (2022)
  5. Stuart ASV, "Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK(Com-COV2) : a single-blind, randomised, phase 2, non-inferiority trial", Lancet, 399, pp.36~49 (2022)
  6. World Health Organization, "Immunization safety surveillance:guidelines for immunization programme managers on surveillance of adverse events following immunization" (2015), World Health Organization
  7. Hervé C, "The how’s and what’s of vaccine reactogenicity", NPJ Vaccines, 4, pp.39~ (2019)
  8. Weekly reports of adverse events following immunization of COVID‐19, "Korea Disease Control and Prevention Agency", Korea Disease Control and Prevention Agency, ~ (2022)
  9. Heath PT, "Safety and efficacy of NVX-CoV2373Covid-19 vaccine", N Engl J Med, 385(13), pp.1172~1183 (2021)
  10. Gambichler T, "Cutaneous findings following COVID-19 vaccination : review of world literature and own experience", J Eur Acad Dermatol Venereol, 36(2), pp.172~180 (2022)
  11. McMahon DE, "Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP : a registry-based study", J Am Acad Dermatol, 86(1), pp.113~121 (2022)
  12. Risma KA, "Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines", J Allergy Clin Immunol, 147(6), pp.2075~2082 (2021)
  13. Bogdanov G, "Cutaneous adverse effects of the available COVID-19vaccines", Clin Dermatol, 39(3), pp.523~531 (2021)
  14. Baden LR, "Efficacy and safety of the mRNA-1273SARS-CoV-2 vaccine", N Engl J Med, 384(5), pp.403~416 (2021)
  15. Johnston MS, "Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine : a case series", JAMA Dermatol, 157(6), pp.716~720 (2021)
  16. Lopatynsky-Reyes EZ, "BCG scar local skin inflammation as a novel reaction following mRNA COVID-19 vaccines in two international healthcare workers", Cureus, 13(4), pp.e14453~ (2021)
  17. Michon A, "Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination : a case report", J Cosmet Dermatol, 20(9), pp.2684~2690 (2021)
  18. Guimarães LE, "Vaccines, adjuvants and autoimmunity", Pharmacol Res, 100, pp.190~209 (2015)
  19. McMahon DE, "Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination : a registry-based study of 414 cases", J Am Acad Dermatol, 85(1), pp.46~55 (2021)
  20. Rodríguez-Jiménez P, "Varicella-zoster virus reactivation after SARS-CoV-2BNT162b2 mRNA vaccination : report of 5 cases", JAAD Case Rep, 12, pp.58~59 (2021)
  21. Aldien AS, "Systemic inflammation may induce cardiac injury in COVID-19 patients including children and adolescents without underlying cardiovascular diseases : a systematic review", Cardiovasc Revasc Med, 35, pp.169~178 (2022)
  22. Segal Y, "Vaccine-induced autoimmunity : the role of molecular mimicry and immune crossreaction", Cell Mol Immunol, 15(6), pp.586~594 (2018)
  23. Polack FP, "Safety and efficacy of the BNT162b2mRNA Covid-19 vaccine", N Engl J Med, 383(27), pp.2603~2615 (2020)
  24. Al-Ali D, "Cardiovascular and haematological events post COVID-19 vaccination : a systematic review", J Cell Mol Med, 26(3), pp.636~653 (2022)
  25. Su JR, "Myopericarditis after vaccination, vaccine adverse event reporting system(VAERS), 1990–2018", Vaccine, 39(5), pp.839~845 (2021)
  26. Tschöpe C, "Myocarditis and inflammatory cardiomyopathy : current evidence and future directions", Nat Rev Cardiol, 18(3), pp.169~193 (2021)
  27. Fairweather D, "Sex and gender differences in myocarditis and dilated cardiomyopathy", Curr Probl Cardiol, 38(1), pp.7~46 (2013)
  28. Patone M, "Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19vaccination or SARS-CoV-2 infection", Nat Med, 28(2), pp.410~422 (2022)
  29. Li M, "Myocarditis and pericarditis following COVID-19 vaccination : inequalities in age and vaccine types", J Pers Med, 11(11), pp.1106~ (2021)
  30. Diaz GA, "Myocarditis and pericarditis after vaccination for COVID-19", J Am Med Assoc, 326(12), pp.1210~1212 (2021)
  31. Meylan S, "Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination", Hypertension, 77(6), pp.e56~e57 (2021)
  32. Smadja DM, "Vaccination against COVID-19 : insight from arterial and venous thrombosis occurrence using data from VigiBase", Eur Respir J, 58(1), pp.2100956~ (2021)
  33. Boivin Z, "Untimely myocardial infarction or COVID-19 vaccine side effect", Cureus, 13(3), pp.e13651~ (2021)
  34. Merchant HA, "CoViD vaccines and thrombotic events : EMA issued warning to patients and healthcare professionals", J Pharm Policy Pract, 14, pp.32~ (2021)
  35. Garg RK, "Spectrum of neurological complications following COVID-19 vaccination", Neurol Sci, 43(1), pp.3~40 (2022)
  36. Hause AM, "Anxiety-related adverse event clusters after Janssen COVID-19 vaccination–five U. S. mass vaccination sites, April 2021", MMWR Morb Mortal Wkly Rep, 70(18), pp.685~688 (2021)
  37. Göbel CH, "Headache attributed to vaccination against COVID-19(coronavirus SARS-CoV-2)with the ChAdOx1 nCoV-19(AZD1222)vaccine : a multicenter observational cohort study", Pain Ther, 10(2), pp.1309~1330 (2021)
  38. Scully M, "Pathologic antibodies to platelet factor 4after ChAdOx1 nCoV-19 vaccination", N Engl J Med, 384(23), pp.2202~2211 (2021)
  39. Krzywicka K, "Pathologic antibodies to post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis : an analysis of cases notified to the European Medicines Agency", Eur J Neurol, 28(11), pp.3656~3662 (2021)
  40. Pavord S, "Clinical features of vaccine-induced immune thrombocytopenia and thrombosis", N Engl J Med, 385(18), pp.1680~1689 (2021)
  41. Makris M, "Vaccine-induced immune thrombocytopenia and thrombosis(VITT)", Res Pract Thromb Haemost, 5(5), pp.e12529~ (2021)
  42. OzonoffA, "Bell’s palsy and SARSCoV-2 vaccines", Lancet Infect Dis, 21(4), pp.450~452 (2021)
  43. Chen Y, "New-onset autoimmune phenomena post-COVID-19vaccination", Immunology, 165(4), pp.386~401 (2022)
  44. Ozgen Kenangil G, "Acute disseminated encephalomyelitis-like presentation after an inactivated coronavirus vaccine", Acta Neurol Belg, 121(4), pp.1089~1091 (2021)
  45. Cao L, "Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination : a case report", Acta Neurol Belg (2021)[DOI]
  46. Cecinati V, "Vaccine administration and the development of immune thrombocytopenic purpura in children", Hum Vaccin Immunother, 9(5), pp.1158~1162 (2013)
  47. Chong KM, "Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor: a case report", Am J Emerg Med (2022)
  48. Waqar SHB, "Thrombotic thrombocytopenic purpura : a new menace after COVID bnt162b2 vaccine", Int J Hematol, 114(5), pp.626~629 (2021)
  49. Radwi M, "A case report of acquired hemophilia following COVID-19 vaccine", J Thromb Haemost, 19(6), pp.1515~1518 (2021)
  50. Park JY, "COVID-19 vaccine-related interstitial lung disease : a case study", Thorax, 77(1), pp.102~104 (2022)
  51. Yoshifuji A, "COVID-19 vaccine induced interstitial lung disease", J Infect Chemother, 28(1), pp.95~98 (2022)
  52. Numata T, "Seasonal influenza vaccine-induced pneumonitis presenting with multiple pulmonary nodules", Intern Med, 57(5), pp.707~711 (2018)
  53. Watanabe S, "Influenza vaccine-induced interstitial lung disease", Eur Respir J, 41(2), pp.474~477 (2013)
  54. Tan L, "Diffuse alveolar damage in BCGosis : a rare complication of intravesical bacillus Calmette-Guérin therapy for transitional cell carcinoma", Pathology, 31(1), pp.55~56 (1999)
  55. Tun GSZ, "Immunemediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed", J Hepatol, 76(3), pp.747~749 (2022)
  56. Tan CK, "Autoimmune hepatitis following COVID-19 vaccination : true causality or mere association?", J Hepatol, 75(5), pp.1250~1252 (2021)
  57. Zettinig G, "Two further cases of Graves’ disease following SARS-Cov-2 vaccination", J Endocrinol Invest, 45(1), pp.227~228 (2022)
  58. Vera-Lastra O, "Two cases of Graves’ disease following SARS-CoV-2 vaccination : an autoimmune", inflammatory syndrome induced by adjuvants, 2021, pp.31(9), 1436~1439
  59. Muller I, "SARS-CoV-2-related atypical thyroiditis", Lancet Diabetes Endocrinol, 8(9), pp.739~741 (2020)
  60. Jiméimez-Blanco S, "COVID-19 : a cause of recurrent Graves’ hyperthyroidism?", J Endocrinol Invest, 44(2), pp.387~388 (2021)
  61. Iba T, "Recognizing vaccine-induced immune thrombotic thrombocytopenia", Crit Care Med, 50(1), pp.e80~e86 (2022)
  62. "Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19)" (2021)[URL]
  63. "Guide to thrombosis with thrombocytopenia syndrome following immunization of COVID‐19 for physicians" (2021)[URL]
  64. Bozkurt B, "Myocarditis with COVID-19 mRNA vaccines", Circulation, 144(6), pp.471~484 (2021)
  65. "Guide to myocarditis and pericarditis following immunization of COVID‐19 for physicians 2-1 edition" (2021)[URL]
  66. "Safety Platform for Emergency vACcines: SO2-D2.5.2.1–AESI case definition companion guide for 1st Tier AESI: anaphylaxis" (2021)[URL]
  67. Turner PJ, "COVID-19 vaccine-associated anaphylaxis : a statement of the World Allergy Organization Anaphylaxis Committee", World Allergy Organ J, 14(2), pp.100517~ (2021)
  68. Kim Mi-Ae, "COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria", Angioedema, Allergy, Asthma & Immunology Research, pp.2021, 13(4)[DOI]
  69. Stone CA Jr, "Immediate hypersensitivity to polyethylene glycols and polysorbates : more common than we have recognized", J Allergy Clin Immunol Pract, 7(5), pp.1533~1540 (2019)
  70. Wenande E, "Immediate-type hypersensitivity to polyethylene glycols : a review", Clin Exp Allergy, 46(7), pp.907~922 (2016)
  71. Banerji A, "mRNA vaccines to prevent COVID-19 disease and reported allergic reactions : current evidence and suggested approach", J Allergy Clin Immunol Pract, 9(4), pp.1423~1437 (2021)
  72. Sellaturay P, "Polyethylene glycol–induced systemic allergic reactions(anaphylaxis)", J Allergy Clin Immunol Pract, 9(2), pp.670~675 (2021)
  73. Cabanillas B, "Allergy to COVID-19 vaccines : a current update", Allergol Int, 70(3), pp.313~318 (2021)
  74. Simons FER, "World Allergy Organization anaphylaxis guidelines : summary", J Allergy Clin Immunol, 127(3), pp.587~593 (2011)
  75. Leonhard SE, "Diagnosis and management of Guillain-Barré syndrome in ten steps", Nat Rev Neurol, 15(11), pp.671~683 (2019)
  76. Hall VJ, "COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2mRNA vaccine against infection(SIREN) : a prospective, multicentre, cohort study", Lancet, 397(10286), pp.1725~1735 (2021)
  77. 김영롱, "코로나 백신 접종을 위한 의료기관 준비사항", 의료관련감염관리, 26(1), pp.3~15 (2021), 대한의료관련감염관리학회[DOI]

관련 논문AI추천

코로나바이러스감염증-19 (coronavirus disease 2019) 백신과 이상 반응정은희대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2021 · 제9권 제3호소아청소년에서 Coronavirus Disease 2019 백신에 대한 이상 반응이은, 김경훈, 김민지, 양현종, 염혜영, 이미희, 이용주대한 소아알레르기 호흡기학회 · Allergy Asthma & Respiratory Disease2022 · 제10권 제1호Cutaneous Adverse Reaction After COVID-19 Vaccination국형돈, 안지영, 정혜정대한의진균학회 · 대한의진균학회지2022 · 제27권 제3호COVID-19 백신 접종 후 발생한 다발성 농양 1예: 증례 보고김갑래, 김태호, 이효범대한족부족관절학회 · 대한족부족관절학회지2023 · 제27권 제2호Covid-19 백신 접종 후 나타나는 피부 상태 반응 또는 다른 장애의 징후권기한, 임수연한국피부과학연구원 · 아시안뷰티화장품학술지2022 · 제20권 제4호COVID-19 Vaccination in KoreaCheong Hee Jin, Hwang Young Hoon, Park Wan Beom대한감염학회 · Infection and Chemotherapy2023 · 제55권 제1호

이 간행물의 다른 논문 (9건)

폐쇄성 수면무호흡증 개선을 위한 상기도 근기능운동박찬순pp. 39-43비용종을 동반한 만성 비부비동염의 치료로서 생물학적 제제의 효과양승구, 김대우pp. 44-52후각 장애를 위한 후각 훈련조규섭, 김성동pp. 53-58Palatine Tonsil Size Predicts Upper Airway Obstruction in Adults with Obstructive Sleep Apnea고태경, 우주영, 구수권, 지창록pp. 59-65진주종으로 오인된 중이의 과오종 1예김상준, 강명구, 허재원, 박민경pp. 66-70
원문 보기